...
首页> 外文期刊>Washington Drug Letter >Amag Hopes for March Marketing Of Anemia Drug
【24h】

Amag Hopes for March Marketing Of Anemia Drug

机译:Amag希望3月上市贫血药物

获取原文
获取原文并翻译 | 示例
           

摘要

Amag Pharmaceuticals has received a complete response letter from the FDA for its key product candidate, and says it hopes to bring the drug to market by the end of March. Ferumoxytol is intended as an intravenous iron replacement to treat iron-deficiency anemia in chronic kidney disease patients and as a diagnostic agent for vascular-enhanced MRI to assess peripheral arterial disease. Amag submitted an NDA for the drug last December. "The company believes that it can address the issues raised by the FDA in its complete response letter in a timely manner without conducting any additional clinical trials prior to approval," the firm says in a statement.
机译:Amag Pharmaceuticals已收到FDA对其主要候选药物的完整回复信,并表示希望在3月底将这种药物推向市场。 Ferumoxytol旨在作为静脉铁剂替代品,用于治疗慢性肾脏病患者的铁缺乏性贫血,并用作血管增强MRI的诊断剂,以评估周围动脉疾病。 Amag去年12月提交了该药物的保密协议。该公司在一份声明中说:“该公司认为,它可以在其完整的答复函中及时解决FDA提出的问题,而无需在批准前进行任何其他临床试验。”

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号